Background: Diffuse large B-cell lymphoma (DLBCL) is classified into germinal center B-cell-like (GCB) and non-GCB subtypes. This study aimed to evaluate the immunohistochemical expression of CTLA-4 in these subtypes and its association with prognostic factors.
Methods: This retrospective study analyzed 50 cases of DLBCL. Clinical and histopathological data were collected, and CTLA-4 expression was assessed using immunohistochemistry. Statistical significance was determined using an unpaired t-test.
Result: The average CTLA-4 expression in DLBCL was 50.46 cells per high-power field. Higher CTLA-4 expression was observed in the non-GCB subtype, patients younger than 60 years, females, those with stage III-IV disease, involvement of more than one extranodal site, and a low International Prognostic Index (IPI) score (0-2). A significant association was found between CTLA-4 expression and age (p = 0.045, 95% CI: 44.67-75.86).
Conclusion: CTLA-4 expression was present in the tumor microenvironment of DLBCL. Higher expression was significantly associated with patients younger than 60 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.31557/APJCP.2025.26.2.405 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of TIM-3 in Glioblastoma Progression.
Cells
February 2025
Fiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.
Several immunoregulatory or immune checkpoint receptors including T cell immunoglobulin and mucin domain 3 (TIM-3) have been implicated in glioblastoma progression. Rigorous investigation over the last decade has elucidated TIM-3 as a key player in inhibiting immune cell activation and several key associated molecules have been identified both upstream and downstream that mediate immune cell dysfunction mechanistically. However, despite several reviews being published on other immune checkpoint molecules such as PD-1 and CTLA-4 in the glioblastoma setting, no such extensive review exists that specifically focuses on the role of TIM-3 in glioblastoma progression and immunosuppression.
View Article and Find Full Text PDFNab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial.
Front Immunol
March 2025
Gastric Cancer Center, Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Background: Gastric cancer (GC) is one of the most prevalent malignant tumors worldwide, often diagnosed at an advanced stage with a poor prognosis. Paclitaxel, nab-paclitaxel, and irinotecan, either as monotherapies or in combination with ramucirumab, are currently standard second-line treatments for GC. However, the efficacy of these therapies is limited, necessitating the development of new combination strategies to improve response rates.
View Article and Find Full Text PDFPD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome.
NPJ Genom Med
March 2025
Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin Cancer Center, Milwaukee, WI, USA.
Programmed cell death protein 1 (PD-1) is a critical immune checkpoint receptor and a target for cancer immune checkpoint inhibitors (ICI). We investigated PD-1 transcript expression across cancer types and its correlations to clinical outcomes. Using a reference population, PD-1 expression was calculated as percentiles in 489 of 514 patients (31 cancer types) with advanced/metastatic disease.
View Article and Find Full Text PDFCharacterization of the immune cell infiltration patterns in lung adenocarcinoma to facilitate immunotherapy.
Heliyon
February 2025
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Although Immunotherapy has emerged as an efficient treatment in lung carcinoma, merely a subset of lung adenocarcinoma (LUAD) patients could be benefited from it. Increasing evidence revealed that tumor immune cell infiltrating (ICI) in the tumor microenvironment (TME) is highly related to patient prognosis and characteristics of the tumor. Thus far, the immune cell infiltration patterns of LUAD remain unclear.
View Article and Find Full Text PDFUse of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis.
Lung Cancer
March 2025
Medical Oncology Department, Hospital Clínic de València, Av. de Blasco Ibáñez, 17, El Pla del Real, 46010 València, Spain; INCLIVA Biomedical Research Institute, C. de Menéndez y Pelayo, 4, El Pla del Real, 46010 València, Spain.
Non-small cell lung cancer (NSCLC) constitutes 80-85% of lung cancer cases and is a leading cause of cancer-related mortality. Most patients are diagnosed at metastatic stages, where curative treatment is rarely an option and the primary goal is to prolong survival while maintaining quality of life. Since NSCLC is often diagnosed in elderly individuals, comorbidities must also be considered in the treatment planning.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!